Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00329303
Recruitment Status : Completed
First Posted : May 24, 2006
Results First Posted : May 6, 2019
Last Update Posted : May 6, 2019
Sponsor:
Information provided by (Responsible Party):
UCB Pharma

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The primary objective is to assess differences in PASI scores between Week 12 of Study C87040 [NCT00245765] and Week 12 of re-treatment in this study.

Condition or disease Intervention/treatment Phase
Psoriasis Drug: Certolizumab Pegol (Cimzia®) Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 71 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Follow-up of Study C87040: Multicentre, Double-blind Study to Describe the Efficacy and Safety of Re-treatment With CDP870 (Certolizumab Pegol) Subcutaneous at 2 Different Dose Regimens (400 mg Initial Dose at Week 0 With 200 mg Every 2 Weeks Thereafter and 400 mg Every 2 Weeks) or Placebo for 12 Weeks, in Subjects Suffering From Moderate-to-severe Chronic Plaque Psoriasis Who Are Candidates for Systemic Therapy and/or Phototherapy and/or Photochemotherapy, Having Responded to Treatment in Study C87040 and Having Subsequently Relapsed
Study Start Date : April 2006
Actual Primary Completion Date : May 2007
Actual Study Completion Date : May 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Certolizumab Pegol (CZP) 200 mg
Subcutaneous injections of 400 mg initial dose at Week 0 with 200 mg every 2 weeks thereafter.
 Drug: Certolizumab Pegol (Cimzia®)
  • Pharmaceutical Form: Solution for injection in pre-filled syringe
  • Route of Administration: Subcutaneous use

  • Dose and Administration details :

    2 x 1 mL Certolizumab Pegol at Week 0, followed by

  • 1 x 1 mL Certolizumab Pegol plus 1 x 1 mL Placebo (for blinding reasons) in the Certolizumab Pegol 200 mg arm at Weeks 2, 4, 6, 8 and 10
  • 2 x 1 mL Certolizumab Pegol in the Certolizumab Pegol 400 mg arm at Weeks 2, 4, 6, 8 and 10
Experimental: Certolizumab Pegol (CZP) 400 mg
Subcutaneous injections of 400 mg every 2 weeks.
 Drug: Certolizumab Pegol (Cimzia®)
  • Pharmaceutical Form: Solution for injection in pre-filled syringe
  • Route of Administration: Subcutaneous use

  • Dose and Administration details :

    2 x 1 mL Certolizumab Pegol at Week 0, followed by

  • 1 x 1 mL Certolizumab Pegol plus 1 x 1 mL Placebo (for blinding reasons) in the Certolizumab Pegol 200 mg arm at Weeks 2, 4, 6, 8 and 10
  • 2 x 1 mL Certolizumab Pegol in the Certolizumab Pegol 400 mg arm at Weeks 2, 4, 6, 8 and 10


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Difference in Psoriasis Activity and Severity Index (PASI) Scores Between Week 12 of the First Treatment in Study C87040 [NCT00245765] and Week 12 of Re-treatment in This Study [ Time Frame: Week 12 in C87040 [NCT00245765] and Week 12 in this study ]
    The PASI is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0=no disease, the maximum score is 72=maximal disease. The difference was calculated by 'PASI score at re-treatment Week 12' minus 'PASI score at First Treatment Week 12'.


Secondary Outcome Measures :
  1. Achievement of a Psoriasis Activity and Severity Index (PASI75) Response at Week 12 of Re-treatment Period From First Treatment Baseline in Study C87040 [ Time Frame: Week 12 ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    PASI75 response at Week 12 of re-treatment is defined as a decrease in PASI score at Week 12 in this study from Baseline in study C87040 of at least 75 %.


  2. Achievement of a Psoriasis Activity and Severity Index (PASI75) Response at Week 12 of Re-treatment Period From Re-treatment Baseline in This Study [ Time Frame: Week 12 ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    PASI75 response at Week 12 of re-treatment is defined as a decrease in PASI score at Week 12 in this study from Baseline in this study of at least 75 %.


  3. Achievement of a Psoriasis Activity and Severity Index (PASI50) Response at Week 12 of Re-treatment Period From First Treatment Baseline in Study C87040 [ Time Frame: Week 12 ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    PASI50 response at Week 12 of re-treatment is defined as a decrease in PASI score at Week 12 in this study from Baseline in study C87040 of at least 50 %.


  4. Achievement of a Psoriasis Activity and Severity Index (PASI50) Response at Week 12 of Re-treatment Period From Re-treatment Baseline in This Study [ Time Frame: Week 12 ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    PASI50 response at Week 12 of re-treatment is defined as a decrease in PASI score at Week 12 in this study from Baseline in this study of at least 50 %.


  5. Achievement of a Psoriasis Activity and Severity Index (PASI90) Response at Week 12 of Re-treatment Period From First Treatment Baseline in Study C87040 [ Time Frame: Week 12 ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    PASI90 response at Week 12 of re-treatment is defined as a decrease in PASI score at Week 12 in this study from Baseline in study C87040 of at least 90 %.


  6. Achievement of a Psoriasis Activity and Severity Index (PASI90) Response at Week 12 of Re-treatment Period From Re-treatment Baseline in This Study [ Time Frame: Week 12 ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    PASI90 response at Week 12 of re-treatment is defined as a decrease in PASI score at Week 12 in this study from Baseline in this study of at least 90 %.


  7. Psoriasis Activity and Severity Index (PASI) Score at First Treatment Baseline in Study C87040 [ Time Frame: First treatment Baseline in study C87040 ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity.


  8. Psoriasis Activity and Severity Index (PASI) Score at Week 1 of First Treatment Period in Study C87040 [ Time Frame: Week 1 of first treatment Period in study C87040 ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity.


  9. Psoriasis Activity and Severity Index (PASI) Score at Week 2 of First Treatment Period in Study C87040 [ Time Frame: Week 2 of first treatment Period in study C87040 ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity.


  10. Psoriasis Activity and Severity Index (PASI) Score at Week 3 of First Treatment Period in Study C87040 [ Time Frame: Week 3 of first treatment Period in study C87040 ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity.


  11. Psoriasis Activity and Severity Index (PASI) Score at Week 4 of First Treatment Period in Study C87040 [ Time Frame: Week 4 of first treatment Period in study C87040 ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity.


  12. Psoriasis Activity and Severity Index (PASI) Score at Week 6 of First Treatment Period in Study C87040 [ Time Frame: Week 6 of first treatment Period in study C87040 ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity.


  13. Psoriasis Activity and Severity Index (PASI) Score at Week 8 of First Treatment Period in Study C87040 [ Time Frame: Week 8 of first treatment Period in study C87040 ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity.


  14. Psoriasis Activity and Severity Index (PASI) Score at Week 10 of First Treatment Period in Study C87040 [ Time Frame: Week 10 of first treatment Period in study C87040 ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity.


  15. Psoriasis Activity and Severity Index (PASI) Score at Week 12 of First Treatment Period in Study C87040 [ Time Frame: Week 12 of first treatment Period in study C87040 ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity.


  16. Psoriasis Activity and Severity Index (PASI) Score at Re-treatment Baseline in This Study [ Time Frame: Re-treatment Baseline in this study ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity.


  17. Psoriasis Activity and Severity Index (PASI) Score at Week 2 of Re-treatment Period in This Study [ Time Frame: Week 2 of re-treatment Period in this study ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity.


  18. Psoriasis Activity and Severity Index (PASI) Score at Week 4 of Re-treatment Period in This Study [ Time Frame: Week 4 of re-treatment Period in this study ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity.


  19. Psoriasis Activity and Severity Index (PASI) Score at Week 6 of Re-treatment Period in This Study [ Time Frame: Week 6 of re-treatment Period in this study ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity.


  20. Psoriasis Activity and Severity Index (PASI) Score at Week 8 of Re-treatment Period in This Study [ Time Frame: Week 8 of re-treatment Period in this study ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity.


  21. Psoriasis Activity and Severity Index (PASI) Score at Week 10 of Re-treatment Period in This Study [ Time Frame: Week 10 of re-treatment Period in this study ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity.


  22. Psoriasis Activity and Severity Index (PASI) Score at Week 12 of Re-treatment Period in This Study [ Time Frame: Week 12 of re-treatment Period in this study ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity.


  23. Psoriasis Activity and Severity Index (PASI) Score at Last Re-treatment Visit in This Study [ Time Frame: Last re-treatment visit in this study ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity.


  24. Percentage Change in Psoriasis Activity and Severity Index (PASI) Score From First Treatment Baseline in Study C87040 to Week 1 of First Treatment Period in C87040 [ Time Frame: From first treatment Baseline in study C87040 to Week 1 of first treatment Period in C87040 ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity. A positive value in percentage change from Baseline indicates an improvement from Baseline.


  25. Percentage Change in Psoriasis Activity and Severity Index (PASI) Score From First Treatment Baseline in Study C87040 to Week 2 of First Treatment Period in C87040 [ Time Frame: From first treatment Baseline in study C87040 to Week 2 of first treatment Period in C87040 ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity. A positive value in percentage change from Baseline indicates an improvement from Baseline.


  26. Percentage Change in Psoriasis Activity and Severity Index (PASI) Score From First Treatment Baseline in Study C87040 to Week 3 of First Treatment Period in C87040 [ Time Frame: From first treatment Baseline in study C87040 to Week 3 of first treatment Period in C87040 ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity. A positive value in percentage change from Baseline indicates an improvement from Baseline.


  27. Percentage Change in Psoriasis Activity and Severity Index (PASI) Score From First Treatment Baseline in Study C87040 to Week 4 of First Treatment Period in C87040 [ Time Frame: From first treatment Baseline in study C87040 to Week 4 of first treatment Period in C87040 ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity. A positive value in percentage change from Baseline indicates an improvement from Baseline.


  28. Percentage Change in Psoriasis Activity and Severity Index (PASI) Score From First Treatment Baseline in Study C87040 to Week 6 of First Treatment Period in C87040 [ Time Frame: From first treatment Baseline in study C87040 to Week 6 of first treatment Period in C87040 ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity. A positive value in percentage change from Baseline indicates an improvement from Baseline.


  29. Percentage Change in Psoriasis Activity and Severity Index (PASI) Score From First Treatment Baseline in Study C87040 to Week 8 of First Treatment Period in C87040 [ Time Frame: From first treatment Baseline in study C87040 to Week 8 of first treatment Period in C87040 ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity. A positive value in percentage change from Baseline indicates an improvement from Baseline.


  30. Percentage Change in Psoriasis Activity and Severity Index (PASI) Score From First Treatment Baseline in Study C87040 to Week 10 of First Treatment Period in C87040 [ Time Frame: From first treatment Baseline in study C87040 to Week 10 of first treatment Period in C87040 ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity. A positive value in percentage change from Baseline indicates an improvement from Baseline.


  31. Percentage Change in Psoriasis Activity and Severity Index (PASI) Score From First Treatment Baseline in Study C87040 to Week 12 of First Treatment Period in C87040 [ Time Frame: From first treatment Baseline in study C87040 to Week 12 of first treatment in C87040 ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity. A positive value in percentage change from Baseline indicates an improvement from Baseline.


  32. Percentage Change in Psoriasis Activity and Severity Index (PASI) Score From First Treatment Baseline in Study C87040 to Re-treatment Baseline in This Study [ Time Frame: From first treatment Baseline in study C87040 to re-treatment Baseline in this study ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity. A positive value in percentage change from Baseline indicates an improvement from Baseline.


  33. Percentage Change in Psoriasis Activity and Severity Index (PASI) Score From First Treatment Baseline in Study C87040 to Week 2 of Re-treatment Period in This Study [ Time Frame: From first treatment Baseline in study C87040 to Week 2 of re-treatment Period in this study ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity. A positive value in percentage change from Baseline indicates an improvement from Baseline.


  34. Percentage Change in Psoriasis Activity and Severity Index (PASI) Score From First Treatment Baseline in Study C87040 to Week 4 of Re-treatment Period in This Study [ Time Frame: From first treatment Baseline in study C87040 to Week 4 of re-treatment Period in this study ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity. A positive value in percentage change from Baseline indicates an improvement from Baseline.


  35. Percentage Change in Psoriasis Activity and Severity Index (PASI) Score From First Treatment Baseline in Study C87040 to Week 6 of Re-treatment Period in This Study [ Time Frame: From first treatment Baseline in study C87040 to Week 6 of re-treatment Period in this study ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity. A positive value in percentage change from Baseline indicates an improvement from Baseline.


  36. Percentage Change in Psoriasis Activity and Severity Index (PASI) Score From First Treatment Baseline in Study C87040 to Week 8 of Re-treatment Period in This Study [ Time Frame: From first treatment Baseline in study C87040 to Week 8 of re-treatment Period in this study ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity. A positive value in percentage change from Baseline indicates an improvement from Baseline.


  37. Percentage Change in Psoriasis Activity and Severity Index (PASI) Score From First Treatment Baseline in Study C87040 to Week 10 of Re-treatment Period in This Study [ Time Frame: From first treatment Baseline in study C87040 to Week 10 of re-treatment Period in this study ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity. A positive value in percentage change from Baseline indicates an improvement from Baseline.


  38. Percentage Change in Psoriasis Activity and Severity Index (PASI) Score From First Treatment Baseline in Study C87040 to Week 12 of Re-treatment Period in This Study [ Time Frame: From first treatment Baseline in study C87040 to Week 12 of re-treatment Period in this study ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity. A positive value in percentage change from Baseline indicates an improvement from Baseline.


  39. Percentage Change in Psoriasis Activity and Severity Index (PASI) Score From First Treatment Baseline in Study C87040 to Last Re-treatment Visit in This Study [ Time Frame: From first treatment Baseline in study C87040 to last re-treatment visit (up to Week 12) in this study ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity. A positive value in percentage change from Baseline indicates an improvement from Baseline.


  40. Percentage Change in Psoriasis Activity and Severity Index (PASI) Score From Re-treatment Baseline in This Study to Week 12 of Re-treatment in This Study [ Time Frame: From re-treatment Baseline in this study to Week 12 of re-treatment in this study ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity. A positive value in percentage change from Baseline indicates an improvement from Baseline.


  41. Best Psoriasis Activity and Severity Index (PASI) Score During the 12 Week First Treatment Period in Study C87040 [ Time Frame: 12 week first treatment Period in study C87040 ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity.


  42. Best Psoriasis Activity and Severity Index (PASI) Score During the 12 Week Re-treatment Period in This Study [ Time Frame: 12 week re-treatment Period in this study ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity.


  43. Time to Reach Best Psoriasis Activity and Severity Index (PASI) Score During the 12 Week First Treatment Period in Study C87040 [ Time Frame: 12 week first treatment Period in study C87040 ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity.


  44. Time to Reach Best Psoriasis Activity and Severity Index (PASI) Score During the 12 Week Re-treatment Period in This Study [ Time Frame: 12 week re-treatment Period in this study ]

    Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.

    The score value ranges from 0 to 72, with higher scores indicating higher Psoriasis activity and severity.


  45. Psoriasis Global Assessment (PGA) Rating at Re-treatment Baseline in This Study [ Time Frame: Re-treatment Baseline in this study ]

    The overall severity of the disease was evaluated using the following 6-point scale:

    5 = Severe: Very marked plaque elevation, scaling, and/or erythema. 4 = Moderate to severe: Marked plaque elevation, scaling, and/or erythema. 3 = Moderate: Moderate plaque elevation, scaling, and/or erythema. 2 = Mild: Slight plaque elevation, scaling, and/or erythema

    1 = Almost clear: Intermediate between mild and clear 0 = Clear: No signs of psoriasis (post-inflammatory hyperpigmentation may be present)


  46. Psoriasis Global Assessment (PGA) Rating at Week 2 of Re-treatment Period in This Study [ Time Frame: Week 2 of re-treatment Period in this study ]

    The overall severity of the disease was evaluated using the following 6-point scale:

    5 = Severe: Very marked plaque elevation, scaling, and/or erythema. 4 = Moderate to severe: Marked plaque elevation, scaling, and/or erythema. 3 = Moderate: Moderate plaque elevation, scaling, and/or erythema. 2 = Mild: Slight plaque elevation, scaling, and/or erythema

    1 = Almost clear: Intermediate between mild and clear 0 = Clear: No signs of psoriasis (post-inflammatory hyperpigmentation may be present)


  47. Psoriasis Global Assessment (PGA) Rating at Week 4 of Re-treatment Period in This Study [ Time Frame: Week 4 of re-treatment Period in this study ]

    The overall severity of the disease was evaluated using the following 6-point scale:

    5 = Severe: Very marked plaque elevation, scaling, and/or erythema. 4 = Moderate to severe: Marked plaque elevation, scaling, and/or erythema. 3 = Moderate: Moderate plaque elevation, scaling, and/or erythema. 2 = Mild: Slight plaque elevation, scaling, and/or erythema

    1 = Almost clear: Intermediate between mild and clear 0 = Clear: No signs of psoriasis (post-inflammatory hyperpigmentation may be present)


  48. Psoriasis Global Assessment (PGA) Rating at Week 6 of Re-treatment Period in This Study [ Time Frame: Week 6 of re-treatment Period in this study ]

    The overall severity of the disease was evaluated using the following 6-point scale:

    5 = Severe: Very marked plaque elevation, scaling, and/or erythema. 4 = Moderate to severe: Marked plaque elevation, scaling, and/or erythema. 3 = Moderate: Moderate plaque elevation, scaling, and/or erythema. 2 = Mild: Slight plaque elevation, scaling, and/or erythema

    1 = Almost clear: Intermediate between mild and clear 0 = Clear: No signs of psoriasis (post-inflammatory hyperpigmentation may be present)


  49. Psoriasis Global Assessment (PGA) Rating at Week 8 of Re-treatment Period in This Study [ Time Frame: Week 8 of re-treatment Period in this study ]

    The overall severity of the disease was evaluated using the following 6-point scale:

    5 = Severe: Very marked plaque elevation, scaling, and/or erythema. 4 = Moderate to severe: Marked plaque elevation, scaling, and/or erythema. 3 = Moderate: Moderate plaque elevation, scaling, and/or erythema. 2 = Mild: Slight plaque elevation, scaling, and/or erythema

    1 = Almost clear: Intermediate between mild and clear 0 = Clear: No signs of psoriasis (post-inflammatory hyperpigmentation may be present)


  50. Psoriasis Global Assessment (PGA) Rating at Week 10 of Re-treatment Period in This Study [ Time Frame: Week 10 of re-treatment Period in this study ]

    The overall severity of the disease was evaluated using the following 6-point scale:

    5 = Severe: Very marked plaque elevation, scaling, and/or erythema. 4 = Moderate to severe: Marked plaque elevation, scaling, and/or erythema. 3 = Moderate: Moderate plaque elevation, scaling, and/or erythema. 2 = Mild: Slight plaque elevation, scaling, and/or erythema

    1 = Almost clear: Intermediate between mild and clear 0 = Clear: No signs of psoriasis (post-inflammatory hyperpigmentation may be present)


  51. Psoriasis Global Assessment (PGA) Rating at Week 12 of Re-treatment Period in This Study [ Time Frame: Week 12 of re-treatment Period in this study ]

    The overall severity of the disease was evaluated using the following 6-point scale:

    5 = Severe: Very marked plaque elevation, scaling, and/or erythema. 4 = Moderate to severe: Marked plaque elevation, scaling, and/or erythema. 3 = Moderate: Moderate plaque elevation, scaling, and/or erythema. 2 = Mild: Slight plaque elevation, scaling, and/or erythema

    1 = Almost clear: Intermediate between mild and clear 0 = Clear: No signs of psoriasis (post-inflammatory hyperpigmentation may be present)


  52. Psoriasis Global Assessment (PGA) Rating at Last Re-treatment Visit in This Study [ Time Frame: Last re-treatment visit in this study ]

    The overall severity of the disease was evaluated using the following 6-point scale:

    5 = Severe: Very marked plaque elevation, scaling, and/or erythema. 4 = Moderate to severe: Marked plaque elevation, scaling, and/or erythema. 3 = Moderate: Moderate plaque elevation, scaling, and/or erythema. 2 = Mild: Slight plaque elevation, scaling, and/or erythema

    1 = Almost clear: Intermediate between mild and clear 0 = Clear: No signs of psoriasis (post-inflammatory hyperpigmentation may be present)


  53. Percentage of Subjects Who Achieve a Psoriasis Global Assessment (PGA) Clear or Almost Clear Response at Week 12 of Re-treatment in This Study [ Time Frame: Week 12 of re-treatment in this study ]

    The overall severity of the disease was evaluated using the following 6-point scale:

    5 = Severe: Very marked plaque elevation, scaling, and/or erythema. 4 = Moderate to severe: Marked plaque elevation, scaling, and/or erythema. 3 = Moderate: Moderate plaque elevation, scaling, and/or erythema. 2 = Mild: Slight plaque elevation, scaling, and/or erythema

    1 = Almost clear: Intermediate between mild and clear 0 = Clear: No signs of psoriasis (post-inflammatory hyperpigmentation may be present)


  54. BSA (Body Surface Area) Affected by Psoriasis at Re-treatment Baseline in This Study [ Time Frame: Re-treatment Baseline in this study ]

    Two methods were used for the evaluation of BSA:

    1. The area of one side of a subject's flat closed hand was used to represent 1 % to the total body surface area (BSA) to estimate the extent of skin involvement in subjects with psoriasis
    2. The rule of nines method assumed that the total BSA comprises head (9 %), anterior trunk (upper, 9 %; lower, 9 %), posterior trunk (upper, 9 %; lower, 9 %), each leg (anterior, 9 %; posterior, 9 %), each arm (9 %) and genitalia (1 %)

  55. BSA (Body Surface Area) Affected by Psoriasis at Week 2 of Re-treatment Period in This Study [ Time Frame: Week 2 of re-treatment Period in this study ]

    Two methods were used for the evaluation of BSA:

    1. The area of one side of a subject's flat closed hand was used to represent 1 % to the total body surface area (BSA) to estimate the extent of skin involvement in subjects with psoriasis
    2. The rule of nines method assumed that the total BSA comprises head (9 %), anterior trunk (upper, 9 %; lower, 9 %), posterior trunk (upper, 9 %; lower, 9 %), each leg (anterior, 9 %; posterior, 9 %), each arm (9 %) and genitalia (1 %)

  56. BSA (Body Surface Area) Affected by Psoriasis at Week 4 of Re-treatment Period in This Study [ Time Frame: Week 4 of re-treatment Period in this study ]

    Two methods were used for the evaluation of BSA:

    1. The area of one side of a subject's flat closed hand was used to represent 1 % to the total body surface area (BSA) to estimate the extent of skin involvement in subjects with psoriasis
    2. The rule of nines method assumed that the total BSA comprises head (9 %), anterior trunk (upper, 9 %; lower, 9 %), posterior trunk (upper, 9 %; lower, 9 %), each leg (anterior, 9 %; posterior, 9 %), each arm (9 %) and genitalia (1 %)

  57. BSA (Body Surface Area) Affected by Psoriasis at Week 6 of Re-treatment Period in This Study [ Time Frame: Week 6 of re-treatment Period in this study ]

    Two methods were used for the evaluation of BSA:

    1. The area of one side of a subject's flat closed hand was used to represent 1 % to the total body surface area (BSA) to estimate the extent of skin involvement in subjects with psoriasis
    2. The rule of nines method assumed that the total BSA comprises head (9 %), anterior trunk (upper, 9 %; lower, 9 %), posterior trunk (upper, 9 %; lower, 9 %), each leg (anterior, 9 %; posterior, 9 %), each arm (9 %) and genitalia (1 %)

  58. BSA (Body Surface Area) Affected by Psoriasis at Week 8 of Re-treatment Period in This Study [ Time Frame: Week 8 of re-treatment Period in this study ]

    Two methods were used for the evaluation of BSA:

    1. The area of one side of a subject's flat closed hand was used to represent 1 % to the total body surface area (BSA) to estimate the extent of skin involvement in subjects with psoriasis
    2. The rule of nines method assumed that the total BSA comprises head (9 %), anterior trunk (upper, 9 %; lower, 9 %), posterior trunk (upper, 9 %; lower, 9 %), each leg (anterior, 9 %; posterior, 9 %), each arm (9 %) and genitalia (1 %)

  59. BSA (Body Surface Area) Affected by Psoriasis at Week 10 of Re-treatment Period in This Study [ Time Frame: Week 10 of re-treatment Period in this study ]

    Two methods were used for the evaluation of BSA:

    1. The area of one side of a subject's flat closed hand was used to represent 1 % to the total body surface area (BSA) to estimate the extent of skin involvement in subjects with psoriasis
    2. The rule of nines method assumed that the total BSA comprises head (9 %), anterior trunk (upper, 9 %; lower, 9 %), posterior trunk (upper, 9 %; lower, 9 %), each leg (anterior, 9 %; posterior, 9 %), each arm (9 %) and genitalia (1 %)

  60. BSA (Body Surface Area) Affected by Psoriasis at Week 12 of Re-treatment Period in This Study [ Time Frame: Week 12 of re-treatment Period in this study ]

    Two methods were used for the evaluation of BSA:

    1. The area of one side of a subject's flat closed hand was used to represent 1 % to the total body surface area (BSA) to estimate the extent of skin involvement in subjects with psoriasis
    2. The rule of nines method assumed that the total BSA comprises head (9 %), anterior trunk (upper, 9 %; lower, 9 %), posterior trunk (upper, 9 %; lower, 9 %), each leg (anterior, 9 %; posterior, 9 %), each arm (9 %) and genitalia (1 %)

  61. BSA (Body Surface Area) Affected by Psoriasis at Last Re-treatment Visit in This Study [ Time Frame: Last re-treatment visit in this study ]

    Two methods were used for the evaluation of BSA:

    1. The area of one side of a subject's flat closed hand was used to represent 1 % to the total body surface area (BSA) to estimate the extent of skin involvement in subjects with psoriasis
    2. The rule of nines method assumed that the total BSA comprises head (9 %), anterior trunk (upper, 9 %; lower, 9 %), posterior trunk (upper, 9 %; lower, 9 %), each leg (anterior, 9 %; posterior, 9 %), each arm (9 %) and genitalia (1 %)

  62. Change in BSA (Body Surface Area) Score From First Treatment Baseline in C87040 to Re-treatment Baseline in This Study [ Time Frame: From first treatment Baseline in C87040 to re-treatment Baseline in this study ]

    Two methods were used for the evaluation of BSA:

    1. The area of one side of a subject's flat closed hand was used to represent 1 % to the total body surface area (BSA) to estimate the extent of skin involvement in subjects with psoriasis
    2. The rule of nines method assumed that the total BSA comprises head (9 %), anterior trunk (upper, 9 %; lower, 9 %), posterior trunk (upper, 9 %; lower, 9 %), each leg (anterior, 9 %; posterior, 9 %), each arm (9 %) and genitalia (1 %) A positive value in Change from Baseline indicates an improvement from Baseline. The higher the positive value, the higher the change.

  63. Change in BSA (Body Surface Area) Score From First Treatment Baseline in C87040 to Week 2 of Re-treatment Period in This Study [ Time Frame: From first treatment Baseline in C87040 to Week 2 of re-treatment Period in this study ]

    Two methods were used for the evaluation of BSA:

    1. The area of one side of a subject's flat closed hand was used to represent 1 % to the total body surface area (BSA) to estimate the extent of skin involvement in subjects with psoriasis
    2. The rule of nines method assumed that the total BSA comprises head (9 %), anterior trunk (upper, 9 %; lower, 9 %), posterior trunk (upper, 9 %; lower, 9 %), each leg (anterior, 9 %; posterior, 9 %), each arm (9 %) and genitalia (1 %) A positive value in Change from Baseline indicates an improvement from Baseline. The higher the positive value, the higher the change.

  64. Change in BSA (Body Surface Area) Score From First Treatment Baseline in C87040 to Week 4 of Re-treatment Period in This Study [ Time Frame: From first treatment Baseline in C87040 to Week 4 of re-treatment Period in this study ]

    Two methods were used for the evaluation of BSA:

    1. The area of one side of a subject's flat closed hand was used to represent 1 % to the total body surface area (BSA) to estimate the extent of skin involvement in subjects with psoriasis
    2. The rule of nines method assumed that the total BSA comprises head (9 %), anterior trunk (upper, 9 %; lower, 9 %), posterior trunk (upper, 9 %; lower, 9 %), each leg (anterior, 9 %; posterior, 9 %), each arm (9 %) and genitalia (1 %) A positive value in Change from Baseline indicates an improvement from Baseline. The higher the positive value, the higher the change.

  65. Change in BSA (Body Surface Area) Score From First Treatment Baseline in C87040 to Week 6 of Re-treatment Period in This Study [ Time Frame: From first treatment Baseline in C87040 to Week 6 of re-treatment Period in this study ]

    Two methods were used for the evaluation of BSA:

    1. The area of one side of a subject's flat closed hand was used to represent 1 % to the total body surface area (BSA) to estimate the extent of skin involvement in subjects with psoriasis
    2. The rule of nines method assumed that the total BSA comprises head (9 %), anterior trunk (upper, 9 %; lower, 9 %), posterior trunk (upper, 9 %; lower, 9 %), each leg (anterior, 9 %; posterior, 9 %), each arm (9 %) and genitalia (1 %) A positive value in Change from Baseline indicates an improvement from Baseline. The higher the positive value, the higher the change.

  66. Change in BSA (Body Surface Area) Score From First Treatment Baseline in C87040 to Week 8 of Re-treatment Period in This Study [ Time Frame: From first treatment Baseline in C87040 to Week 8 of re-treatment Period in this study ]

    Two methods were used for the evaluation of BSA:

    1. The area of one side of a subject's flat closed hand was used to represent 1 % to the total body surface area (BSA) to estimate the extent of skin involvement in subjects with psoriasis
    2. The rule of nines method assumed that the total BSA comprises head (9 %), anterior trunk (upper, 9 %; lower, 9 %), posterior trunk (upper, 9 %; lower, 9 %), each leg (anterior, 9 %; posterior, 9 %), each arm (9 %) and genitalia (1 %) A positive value in Change from Baseline indicates an improvement from Baseline. The higher the positive value, the higher the change.

  67. Change in BSA (Body Surface Area) Score From First Treatment Baseline in C87040 to Week 10 of Re-treatment Period in This Study [ Time Frame: From first treatment Baseline in C87040 to Week 10 of re-treatment Period in this study ]

    Two methods were used for the evaluation of BSA:

    1. The area of one side of a subject's flat closed hand was used to represent 1 % to the total body surface area (BSA) to estimate the extent of skin involvement in subjects with psoriasis
    2. The rule of nines method assumed that the total BSA comprises head (9 %), anterior trunk (upper, 9 %; lower, 9 %), posterior trunk (upper, 9 %; lower, 9 %), each leg (anterior, 9 %; posterior, 9 %), each arm (9 %) and genitalia (1 %) A positive value in Change from Baseline indicates an improvement from Baseline. The higher the positive value, the higher the change.

  68. Change in BSA (Body Surface Area) Score From First Treatment Baseline in C87040 to Week 12 of Re-treatment Period in This Study [ Time Frame: From first treatment Baseline in C87040 to Week 12 of re-treatment Period in this study ]

    Two methods were used for the evaluation of BSA:

    1. The area of one side of a subject's flat closed hand was used to represent 1 % to the total body surface area (BSA) to estimate the extent of skin involvement in subjects with psoriasis
    2. The rule of nines method assumed that the total BSA comprises head (9 %), anterior trunk (upper, 9 %; lower, 9 %), posterior trunk (upper, 9 %; lower, 9 %), each leg (anterior, 9 %; posterior, 9 %), each arm (9 %) and genitalia (1 %) A positive value in Change from Baseline indicates an improvement from Baseline. The higher the positive value, the higher the change.

  69. Change in BSA (Body Surface Area) Score From First Treatment Baseline in C87040 to Last Re-treatment Visit in This Study [ Time Frame: From first treatment Baseline in C87040 to last re-treatment visit (up to Week 12) in this study ]

    Two methods were used for the evaluation of BSA:

    1. The area of one side of a subject's flat closed hand was used to represent 1 % to the total body surface area (BSA) to estimate the extent of skin involvement in subjects with psoriasis
    2. The rule of nines method assumed that the total BSA comprises head (9 %), anterior trunk (upper, 9 %; lower, 9 %), posterior trunk (upper, 9 %; lower, 9 %), each leg (anterior, 9 %; posterior, 9 %), each arm (9 %) and genitalia (1 %) A positive value in Change from Baseline indicates an improvement from Baseline. The higher the positive value, the higher the change.

  70. Change in BSA (Body Surface Area) Score From Re-treatment Baseline in This Study to Week 2 of Re-treatment Period in This Study [ Time Frame: From re-treatment Baseline in this study to Week 2 of re-treatment Period in this study ]

    Two methods were used for the evaluation of BSA:

    1. The area of one side of a subject's flat closed hand was used to represent 1 % to the total body surface area (BSA) to estimate the extent of skin involvement in subjects with psoriasis
    2. The rule of nines method assumed that the total BSA comprises head (9 %), anterior trunk (upper, 9 %; lower, 9 %), posterior trunk (upper, 9 %; lower, 9 %), each leg (anterior, 9 %; posterior, 9 %), each arm (9 %) and genitalia (1 %) A positive value in Change from Baseline indicates an improvement from Baseline. The higher the positive value, the higher the change.

  71. Change in BSA (Body Surface Area) Score From Re-treatment Baseline in This Study to Week 4 of Re-treatment Period in This Study [ Time Frame: From re-treatment Baseline in this study to Week 4 of re-treatment Period in this study ]

    Two methods were used for the evaluation of BSA:

    1. The area of one side of a subject's flat closed hand was used to represent 1 % to the total body surface area (BSA) to estimate the extent of skin involvement in subjects with psoriasis
    2. The rule of nines method assumed that the total BSA comprises head (9 %), anterior trunk (upper, 9 %; lower, 9 %), posterior trunk (upper, 9 %; lower, 9 %), each leg (anterior, 9 %; posterior, 9 %), each arm (9 %) and genitalia (1 %) A positive value in Change from Baseline indicates an improvement from Baseline. The higher the positive value, the higher the change.

  72. Change in BSA (Body Surface Area) Score From Re-treatment Baseline in This Study to Week 6 of Re-treatment Period in This Study [ Time Frame: From re-treatment Baseline in this study to Week 6 of re-treatment Period in this study ]

    Two methods were used for the evaluation of BSA:

    1. The area of one side of a subject's flat closed hand was used to represent 1 % to the total body surface area (BSA) to estimate the extent of skin involvement in subjects with psoriasis
    2. The rule of nines method assumed that the total BSA comprises head (9 %), anterior trunk (upper, 9 %; lower, 9 %), posterior trunk (upper, 9 %; lower, 9 %), each leg (anterior, 9 %; posterior, 9 %), each arm (9 %) and genitalia (1 %) A positive value in Change from Baseline indicates an improvement from Baseline. The higher the positive value, the higher the change.

  73. Change in BSA (Body Surface Area) Score From Re-treatment Baseline in This Study to Week 8 of Re-treatment Period in This Study [ Time Frame: From re-treatment Baseline in this study to Week 8 of re-treatment Period in this study ]

    Two methods were used for the evaluation of BSA:

    1. The area of one side of a subject's flat closed hand was used to represent 1 % to the total body surface area (BSA) to estimate the extent of skin involvement in subjects with psoriasis
    2. The rule of nines method assumed that the total BSA comprises head (9 %), anterior trunk (upper, 9 %; lower, 9 %), posterior trunk (upper, 9 %; lower, 9 %), each leg (anterior, 9 %; posterior, 9 %), each arm (9 %) and genitalia (1 %) A positive value in Change from Baseline indicates an improvement from Baseline. The higher the positive value, the higher the change.

  74. Change in BSA (Body Surface Area) Score From Re-treatment Baseline in This Study to Week 10 of Re-treatment Period in This Study [ Time Frame: From re-treatment Baseline in this study to Week 10 of re-treatment Period in this study ]

    Two methods were used for the evaluation of BSA:

    1. The area of one side of a subject's flat closed hand was used to represent 1 % to the total body surface area (BSA) to estimate the extent of skin involvement in subjects with psoriasis
    2. The rule of nines method assumed that the total BSA comprises head (9 %), anterior trunk (upper, 9 %; lower, 9 %), posterior trunk (upper, 9 %; lower, 9 %), each leg (anterior, 9 %; posterior, 9 %), each arm (9 %) and genitalia (1 %) A positive value in Change from Baseline indicates an improvement from Baseline. The higher the positive value, the higher the change.

  75. Change in BSA (Body Surface Area) Score From Re-treatment Baseline in This Study to Week 12 of Re-treatment Period in This Study [ Time Frame: From re-treatment Baseline in this study to Week 12 of re-treatment Period in this study ]

    Two methods were used for the evaluation of BSA:

    1. The area of one side of a subject's flat closed hand was used to represent 1 % to the total body surface area (BSA) to estimate the extent of skin involvement in subjects with psoriasis
    2. The rule of nines method assumed that the total BSA comprises head (9 %), anterior trunk (upper, 9 %; lower, 9 %), posterior trunk (upper, 9 %; lower, 9 %), each leg (anterior, 9 %; posterior, 9 %), each arm (9 %) and genitalia (1 %) A positive value in Change from Baseline indicates an improvement from Baseline. The higher the positive value, the higher the change.

  76. Change in BSA (Body Surface Area) Score From Re-treatment Baseline in This Study to Last Re-treatment Visit in This Study [ Time Frame: From re-treatment Baseline in this study to last re-treatment visit in this study ]

    Two methods were used for the evaluation of BSA:

    1. The area of one side of a subject's flat closed hand was used to represent 1 % to the total body surface area (BSA) to estimate the extent of skin involvement in subjects with psoriasis
    2. The rule of nines method assumed that the total BSA comprises head (9 %), anterior trunk (upper, 9 %; lower, 9 %), posterior trunk (upper, 9 %; lower, 9 %), each leg (anterior, 9 %; posterior, 9 %), each arm (9 %) and genitalia (1 %) A positive value in Change from Baseline indicates an improvement from Baseline. The higher the positive value, the higher the change.

  77. Time to Withdrawal From the Treatment Due to Lack of Efficacy or Due to AE ('Worsening or Exacerbation of Psoriasis') During the 12 Week Re-treatment Period in This Study [ Time Frame: During the 12 week re-treatment Period in this study ]
    An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject having responded to treatment at Week 12 in study C87040 and having relapsed during the follow-up period
  • Female subjects either postmenopausal for at least one year, surgically incapable of childbearing, or effectively practising an acceptable method of contraception.Subjects agreed to continue using adequate contraception during the study and for 12 weeks after the last dose of CDP870

Exclusion Criteria:

  • Subjects with erythrodermic, guttate, generalized pustular form of psoriasis
  • Any recent serious or life-threatening infection or any current sign or symptom that may indicate an infection (e.g., fever, cough)
  • Positive hepatitis B surface antigen test and /or hepatitis C antibody test results
  • Positive human immunodeficiency virus (HIV) test result
  • White blood cell counts less than 4000 per cubic millimeter or more than 20000 per cubic millimeter
  • Suspected or diagnosed demyelinating disease of the central nervous system (e.g. multiple sclerosis or optic neuritis)
  • Systemic Lupus Erythematosus
  • Participation in a clinical study within the past 3 months except Study C87040
  • Any other condition, which in the Investigator's judgment would make the subject unsuitable for inclusion in the study
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00329303


Locations
Layout table for location information
France
Besançon, France
Créteil, France
Nice Cedex 3, France
Paris, France
Pierre Benite, France
Germany
Berlin, Germany
Bonn, Germany
Essen, Germany
Frankfurt, Germany
Hamburg, Germany
Kiel, Germany
Mahlow, Germany
Mainz, Germany
Munster, Germany
Sponsors and Collaborators
UCB Pharma
Investigators
Layout table for investigator information
Study Director: UCB Cares UCB Pharma
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications of Results:

Layout table for additonal information
Responsible Party: UCB Pharma
ClinicalTrials.gov Identifier: NCT00329303    
Other Study ID Numbers: C87044
2005-005525-63 ( EudraCT Number )
First Posted: May 24, 2006    Key Record Dates
Results First Posted: May 6, 2019
Last Update Posted: May 6, 2019
Last Verified: February 2019
Keywords provided by UCB Pharma:
Moderate to severe chronic plaque psoriasis
anti TNF α
CDP 870
 Cimzia®
certolizumab pegol
retreatment
Additional relevant MeSH terms:
Layout table for MeSH terms
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Certolizumab Pegol
 Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents